After operating in stealth for its first year, Lyora Therapeutics publicly launched in July, announcing Pam Stetkiewicz as the Providence-based biotech company’s CEO. With $2.5 million in pre-seed funding, Lyora develops medications for those living with inherited retinal diseases that currently have no treatment options. The firm is currently developing medications for vision loss and potential blindness caused by retinitis pigmentosa, Usher syndrome and Leber’s congenital amaurosis. PBN: You’ve held roles at several
Already a Subscriber? Log in
To Continue Reading This Article
Become a Providence Business News subscriber and get immediate access to all of our premier content and much more.Learn More and Become a Subscriber
- Critical RI business news and analysis updated daily.
- 1 year of print (26 issues).
- Unlimited access to all subscriber only content on our website, on any device.
- Free email alerts.
- Annual Book of Lists Print Edition.
- All special issues produced during subscription term.
Click Here to purchase a paywall bypass link for this article
PBN Branded Content
Beyond Cash Donations: How New Forms of Giving Are Transforming Not-for-Profit Accounting
Evolving Funding Landscape for Not-for-Profits Not-for-profit organizations are being asked to do more with less,…
Learn More
